Literature DB >> 19949099

CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions.

Sandra Phillips1, Shilpa Chokshi, Antonio Riva, Alexander Evans, Roger Williams, Nikolai V Naoumov.   

Abstract

Resolution of hepatitis B virus (HBV) infection was believed to be attributed to the cytotoxic T cell-mediated killing of infected hepatocytes. However, studies in HBV transgenic mice and HBV-infected chimpanzees revealed that T cell control of HBV replication also involves cytokine-mediated noncytolytic mechanisms. The relative role of cytolytic and noncytolytic functions of virus-specific CD8(+) T cells during interaction with HBV-producing hepatocytes is not well understood. By using HLA-A2 matched effector cells (CD8(+) T cell line or clone) and target cells supporting full HBV replication, we demonstrate that virus-specific CD8(+) T cells can inhibit HBV replication in HBV-producing hepatocytes with minimal cell lysis. Although CD8(+) T cells kill a fraction of infected cells, this effect is minimal, and most of the viral inhibition is mediated by noncytolytic mechanisms. CD8(+) T cells produce an array of cytokines, among which IFN-gamma and TNF-alpha are responsible for HBV inactivation in the target cells. Blockade of IFN-gamma and TNF-alpha abrogated the noncytolytic inhibition of HBV, indicating that these two cytokines mediate the control of HBV by noncytolytic mechanisms. Furthermore, treatment of the HBV-producing hepatocytes with rIFN-gamma and rTNF-alpha resulted in an efficient suppression of viral replication without cytotoxicity. In contrast, coculture of the same target cells with activated HLA-mismatched mitogen-activated lymphomononuclear cells caused a marked cytolytic effect and was less effective in HBV control. These results provide direct evidence that virus-specific CD8(+) T cells efficiently control HBV replication by noncytolytic mechanisms, and this effect is mediated by IFN-gamma and TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19949099     DOI: 10.4049/jimmunol.0902761

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  73 in total

Review 1.  Molecular dialogs between the ischemic brain and the peripheral immune system: dualistic roles in injury and repair.

Authors:  Chengrui An; Yejie Shi; Peiying Li; Xiaoming Hu; Yu Gan; Ruth A Stetler; Rehana K Leak; Yanqin Gao; Bao-Liang Sun; Ping Zheng; Jun Chen
Journal:  Prog Neurobiol       Date:  2013-12-26       Impact factor: 11.685

Review 2.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

3.  MHC-E-Restricted CD8+ T Cells Target Hepatitis B Virus-Infected Human Hepatocytes.

Authors:  Benjamin J Burwitz; Patrick K Hashiguchi; Mandana Mansouri; Christine Meyer; Roxanne M Gilbride; Sreya Biswas; Jennie L Womack; Jason S Reed; Helen L Wu; Michael K Axthelm; Scott G Hansen; Louis J Picker; Klaus Früh; Jonah B Sacha
Journal:  J Immunol       Date:  2020-03-11       Impact factor: 5.422

Review 4.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

5.  Genetic control of hepatitis A severity and susceptibility to allergy.

Authors:  Lucienne Chatenoud; Jean-François Bach
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

6.  Hepatitis B Virus-Infected HepG2hNTCP Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8+ T Cells In Vitro.

Authors:  Alexander Hoh; Maximilian Heeg; Yi Ni; Anita Schuch; Benedikt Binder; Nadine Hennecke; Hubert E Blum; Michael Nassal; Ulrike Protzer; Maike Hofmann; Stephan Urban; Robert Thimme
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

7.  Effects of dendritic cells from hepatitis B virus transgenic mice-stimulated autologous lymphocytes on hepatitis B virus replication: a study on the impact of specific sensitized effector cells on in vitro virus replication.

Authors:  Zhong-Yang Shen; Wei-Ping Zheng; Tao Liu; Yang Yang; Hong-Li Song
Journal:  Viral Immunol       Date:  2014-10-24       Impact factor: 2.257

8.  Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo.

Authors:  Xiaohua Chen; Yuyan Tang; Yi Zhang; Meng Zhuo; Zhenghao Tang; Yongsheng Yu; Guoqing Zang
Journal:  Lab Invest       Date:  2014-03-10       Impact factor: 5.662

Review 9.  Crosstalk between innate and adaptive immunity in hepatitis B virus infection.

Authors:  Li Wang; Kai Wang; Zhi-Qiang Zou
Journal:  World J Hepatol       Date:  2015-12-28

Review 10.  The immune tolerant phase of chronic HBV infection: new perspectives on an old concept.

Authors:  Antonio Bertoletti; Patrick T Kennedy
Journal:  Cell Mol Immunol       Date:  2014-09-01       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.